检索结果-南通市图书馆

科学新闻 2017年第4期 36-36页

作者：高华 goutam Chakraborty Zhanguo Zhang Intissar Akalay Mayur gadiya Yaquan gao Surajit Sinha Jian Hu Cizhong Jiang Muzaffar Akram Edi Brogi Birgit Leitinger filippo g.giancotti 同济大学生命科学与技术学院/转化医学高等研究院同济大学附属东方医院转化医学研究中心美国斯隆癌症中心

文章简介恶性肿瘤具有无限增殖和转移生物学特征。转移导致绝大部分癌症病人死亡,具有重要的临床意义,但是相关生物学基础和分子机制仍然知之甚少。本研究利用小鼠乳腺癌转移模型和之前构建的全基因组水平功能相关的筛选系统,捕获了肿... 详细信息

文章简介恶性肿瘤具有无限增殖和转移生物学特征。转移导致绝大部分癌症病人死亡,具有重要的临床意义,但是相关生物学基础和分子机制仍然知之甚少。本研究利用小鼠乳腺癌转移模型和之前构建的全基因组水平功能相关的筛选系统,捕获了肿瘤特异性表达的四次跨膜蛋白TM4SF1。

关键词：乳腺癌 DDR1 乳腺肿瘤信号通路多器官受体

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

粘附素与肿瘤细胞扩散

引用

国外医学（输血及血液学分册） 1991年第3期14卷 155-157页

作者： Ruoslahti E giancotti Fg 官奇

肿瘤细胞的转移能力部分可以通过它与其它细胞以及细胞外基质成分粘附的相互作用来决定。细胞表面受体——粘附素在这种相互作用中起重要作用。对于各种粘附素在正常和转化细胞中精确作用的研究,可能为将来肿瘤治疗提供设想,本文综述了... 详细信息

肿瘤细胞的转移能力部分可以通过它与其它细胞以及细胞外基质成分粘附的相互作用来决定。细胞表面受体——粘附素在这种相互作用中起重要作用。对于各种粘附素在正常和转化细胞中精确作用的研究,可能为将来肿瘤治疗提供设想,本文综述了这方面的最新进展。

关键词：粘附素肿瘤细胞扩散

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Is neutrophil gelatinase associated lipocalin useful in hepatitis C virus infection?

引用

World Journal of Hepatology 2016年第19期8卷 815-824页

作者： Alessio Strazzulla giuseppe Coppolino Concetta Di Fatta Francesca giancotti giuseppina D'Onofrio Maria Concetta Postorino Maria Mazzitelli Selma Valerie Mammone Innocenza gentile Laura Rivoli Eleonora Palella Tiziana gravina Chiara Costa Vincenzo Pisani Vincenzo De Maria giorgio Settimo Barreca Nadia Marascio Alfredo Focà giorgio Fuiano Elio gulletta Carlo Torti Infectious Diseases Unit Department of Medical and Surgical Sciences "Magna Graecia" University Nephrology and Dialysis Unit "Pugliese-Ciaccio" Hospital Clinical Pathology Unit Department of Health Sciences "Magna Graecia" University Hepatology Unit "Mater Domini" Teaching Hospital Nephrology Unit Department of Medical and Surgical Sciences "Magna Graecia" University Microbiology Unit Department of Health Sciences "Magna Graecia" University

AIM: To evaluate neutrophil gelatinase associated lipocalin(NgAL) in patients infected by hepatitis C virus(HCV) before and during treatment with directly acting antivirals(DAAs).METHODS: NgAL was measured in a group of patients with chronic HCV infection ranked, at baseline, by age, gender, anti-hypertensive therapy, HCV viral load, liver fibrosis stage and, either at baseline or after 1 year, estimated glomerular filtration rate(e gFR). Then, NgAL and e gFR evolutions were monitored in a subgroup of patients who started antiviral therapy with DAAs. Differences of median NgAL levels were evaluated through Wilcoxon-Mann-Whitney test for nonparametric data. Differences in dichotomous variables were evaluated through χ~2 test. At baseline, a univariate regression analysis was conducted to verify if NgAL values correlated with other quantitative variables [age, fibrosis four(FIB-4), AST to platelet ratio index(APRI), and e gFR]. RESULTS: Overall, 48 patients were enrolled, 8 of them starting HCV treatment. At baseline, statistically significant differences were found in median NgAL values only between patients with e gFR gFR ≥ 90 mL/min. Differences in NgAL were not significant among patients ranked by HCV viral load, FIB-4 score and APRI, when patients with NgAL > 118.11 ng/d L were compared with those of NgAL ≤ 118.11 ng/d L, not statistically significant differences were present for age, gender, chronic kidney disease classification and liver fibrosis(P > 0.05). Linear correlation was found between NgAL and both age(P = 0.0475) and e gFR(P = 0.0282) values. Not statistically significant predictions of NgAL at baseline were demonstrated for e gFR evolution 1 year later. Interestingly, in the 8 patients treated with DAAs, median NgAL significantly increased at week 12 compared to baseline(P = 0.0239).CONCLUSION: Our results suggest that NgAL should be further evaluated as an adjunct marker of kidney function in these patients.

关键词： Directly acting antivirals Hepatitis C virus Inflammation Neutrophil gelatinase lipocalin Tubular impairment

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Boceprevir or telaprevir in hepatitis C virus chronic infection:The Italian real life experience

引用

World Journal of Hepatology 2016年第22期8卷 949-956页

作者： Antonio Ascione Luigi Elio Adinolfi Pietro Amoroso Angelo Andriulli Orlando Armignacco Tiziana Ascione Sergio Babudieri giorgio Barbarini Michele Brogna Francesco Cesario Vincenzo Citro Ernesto Claar Raffaele Cozzolongo giuseppe D’Adamo Emilio D’Amico Pellegrino Dattolo Massimo De Luca Vincenzo De Maria Massimo De Siena giuseppe De Vita Antonio Di giacomo Rosanna De Marco giorgio De Stefano giulio De Stefano Sebastiano Di Salvo Raffaele Di Sarno Nunzia Farella Laura Felicioni Basilio Fimiani Luca Fontanella giuseppe Foti Caterina Furlan Francesca giancotti giancarlo giolitto Tiziana gravina Barbara guerrera Roberto gulminetti Angelo Iacobellis Michele Imparato Angelo Iodice Vincenzo Iovinella Antonio Izzi Alfonso Liberti Pietro Leo gennaro Lettieri Ileana Luppino Aldo Marrone Ettore Mazzoni Vincenzo Messina Roberto Monarca Vincenzo Narciso Lorenzo Nosotti Adriano Maria Pellicelli Alessandro Perrella guido Piai Antonio Picardi Paola Pierri grazia Pietromatera Francesco Resta Luca Rinaldi Mario Romano Angelo Rossini Maurizio Russello grazia Russo Rodolfo Sacco Vincenzo Sangiovanni Antonio Schiano Antonio Sciambra gaetano Scifo Filomena Simeone Annarita Sullo Pierluigi Tarquini Paolo Tundo Alfredo Vallone Depart-ment of Medicine Center for Liver Diseases "Buon Consiglio" -Fatebenefratelli Hospital Internal Medicine Unit Second University of Naples VI Division of Infectious Diseases Cotugno Hospital AORN "Ospedali dei Colli" Division of gastro- enterology Casa Sollievo Sofferenza Hospital IRCCS Division of Infectious Diseases Belcolle Hospital IX Division of Infectious Diseases Cotugno Hospital AORN "Ospedali dei Colli" Clinical of Infectious Disease University of Sassari Infectious Disease IRCCS San Matteo Division of Infectious Diseases and Liver Unit "G. Iazzolino" Hospital Division of Infectious Diseases "Annunziata" Hospital Depart-ment of Internal Medicine Umberto I Hospital Internal Medicine Ospedale Evangelico Villa Betania Division of gastroenterology IRCCS "S.de Bellis" Hospital Internal Medicine Unit Pescara-Penne Hospital gastroenterology Unit Marcianise Hospital Liver Unit AORN Cardarelli Liver Unit Policlinico "Mater Domini" Service of Medical Day Hospital "Rummo" Hospital Internal Medicine Regina Margherita Hospital Division of gastroenterology "Annunziata" Hospital Infectious Disease Matera Hospital First Division of Infectious Diseases Cotugno Hospital AORN "Ospedali dei Colli" Division of Infectious Diseases AO Melacrino- Bianchi-Morelli Infectious and Tropical Disease Policlinico Umberto I Division of Infectious Disease Maria SS Addolorata Hospital Division of Infectious Diseases S. Anna and S. Sebastiano Hospital Outpatients Service for Liver Diseases "Loreto Crispi" Hospital V Division of Infectious Diseases Cotugno Hospital AORN "Ospedali dei Colli" Department of Medical Surgical Neurological Geriatric and Metabolic Sciences Second Univer-sity of Naples Liver Unit Policlinico Casilino Medicine and Health Unit for Prisoners Belcolle Hospital Internal Medicine Unit "Ascalesi" Hospital gastrointestinal and Liver Department National Institute for Health Migration and Poverty Liver Unit Azienda Ospedaliera San Camillo Forlanini VII Division of Infectious Diseases

AIM: To check the safety and efficacy of boceprevir/telaprevir with peginterferon/ribavirin for hepatitis C virus(HCV) genotype 1 in the real-world settings. METHODS: This study was a non-randomized, observational, prospective, multicenter. This study involved 47 centers in Italy. A database was prepared for the homogenous collection of the data, was used by all of the centers for data collection, and was updated continuously. All of the patients enrolled in this study were older than 18 years of age and were diagnosed with chronic infection due to HCV genotype 1. The HCV RNA testing was performed using COBAS-Taq Man2.0(Roche, LLQ 25 IU/m L). RESULTS: All consecutively treated patients were included. Forty-seven centers enrolled 834 patients as follows: Male 64%; median age 57(range 18-78), of whom 18.3% were over 65; mean body mass index 25.6(range 16-39); genotype 1b(79.4%); diagnosis of cirrhosis(38.2%); and fibrosis F3/4(71.2%). The following drugs were used: Telaprevir(66.2%) and PEg-IFN-alpha2a(67.6%). Patients were na?ve(24.4%), relapsers(30.5%), partial responders(14.8%) and null responders(30.3%). Overall, adverse events(AEs) occurred in 617 patients(73.9%) during the treatment. Anemia was the most frequent AE(52.9% of cases), especially in cirrhotic. The therapy was stopped for 14.6% of the patients because of adverse events or virological failure(15%). Sustained virological response was achieved in 62.7% of the cases, but was 43.8% in cirrhotic patients over 65 years of age. CONCLUSION: In everyday practice, triple therapy is safe but has moderate efficacy, especially for patients over 65 years of age, with advanced fibrosis, nonresponders to peginterferon + ribavirin.

关键词： Boceprevir Telaprevir Chronic hepatitis Antiviral therapy Peg-interferon Ribavirin

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：